POAI - Predictive Oncology Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.7200
-0.1300 (-4.56%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close2.8500
Open2.9400
Bid0.0000 x 1100
Ask0.0000 x 1000
Day's Range2.7000 - 2.9400
52 Week Range2.3500 - 11.5000
Volume46,683
Avg. Volume42,187
Market Cap11M
Beta (5Y Monthly)2.39
PE Ratio (TTM)N/A
EPS (TTM)-4.1130
Earnings DateNov 15, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Predictive Oncology Provides Updates on Commercialization of Its Cancer Quest 2020 Initiative

    MINNEAPOLIS, Dec. 09, 2019 -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a data and artificial intelligence (“AI”) driven discovery.

  • GlobeNewswire

    Predictive Oncology Confirms Indications of Interest for Skyline Medical Business

    As previously announced, Predictive Oncology has determined that it will focus its resources on its primary mission of applying artificial intelligence to precision medicine and drug discovery. Skyline Medical’s patented, FDA-approved STREAMWAY System is the first truly continuous, direct-to-drain fluid disposal system designed specifically for medical applications.

  • GlobeNewswire

    Predictive Oncology Has Regained Compliance with Nasdaq’s Minimum Bid Price Requirement

    Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that based on a notification letter (the “Notification Letter on Compliance”) recently received from the Listing Qualifications Department of the Nasdaq Stock Market Inc. (the “Nasdaq”), the Company has regained compliance with the minimum bid price requirement set forth in Rule 5550(a)(2) of the Nasdaq Listing Rules (the “Minimum Bid Price Requirement”). On November 16, 2018, the Company received a notification letter from the Nasdaq (the “Notification Letter on Deficiency”) indicating that the closing bid price per share had been below $1.00 for a period of 30 Consecutive business days and that the Company did not meet the Minimum Price Bid Requirement.

  • GlobeNewswire

    Predictive Oncology Secures $15,000,000 Equity Line

    Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it entered into a $15 million common stock purchase and registration rights agreement with Oasis Capital, LLC, a Puerto Rico limited liability company (“Oasis Capital”), to purchase from the Company up to Fifteen Million Dollars ($15,000,000.00) of the Company’s Common Stock. Under the purchase agreement, Predictive Oncology has the right to sell up to $15 million of its stock to Oasis Capital over a 36-month period, upon satisfaction of the conditions in the purchase agreement including the effectiveness of a resale registration statement which has occurred.

  • GlobeNewswire

    Predictive Oncology CEO Discusses Corporate Milestones, Unique Approach to Cancer Research in Exclusive Broadcast

    NEW YORK, Nov. 19, 2019 (GLOBE NEWSWIRE) -- via NetworkNewsAudio – Predictive Oncology Inc. (NASDAQ: POAI), a knowledge-driven precision medicine company focused on applying data and artificial intelligence (AI) to personalized medicine and drug discovery, today announces the broadcast of its audio interview with NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) solution that delivers clients unparalleled visibility, recognition and brand awareness in the investment community. Predictive Oncology CEO Dr. Carl Schwartz joins NNW’s Stuart Smith for a look at the company’s strategy of applying its smart tumor profiling and AI platform to extensive genomic and biomarker patient data sets, allowing them to build predictive models of tumor drug response that will improve clinical outcomes for the cancer patients.

  • GlobeNewswire

    Predictive Oncology Inc. Reports Q3 Results; Revenues Increase 58%

    MINNEAPOLIS, Nov. 15, 2019 -- Predictive Oncology Inc., (NASDAQ: POAI) (“Predictive Oncology” or “the Company”) an artificial intelligence (AI) and data-driven functional.

  • GlobeNewswire

    Predictive Oncology Featured in Broadcast Evaluating Targeted Cancer Therapies, Higher Survival Rates

    There’s a paradigm shift occurring in cancer therapeutics, and ovarian cancer patients look to be the beneficiaries. Treatment protocols for ovarian cancer have historically consisted of a combination of surgery and chemotherapy. Predictive Oncology’s subsidiary, Helomics, currently has about 150,000 cases on its molecular information platform, 38,000 of which are specific to ovarian cancer.

  • GlobeNewswire

    Predictive Oncology Featured in Publication Discussing the Impact of Artificial Intelligence on Cancer Treatment

    NEW YORK, Nov. 06, 2019 (GLOBE NEWSWIRE) -- via NetworkWire — Predictive Oncology (NASDAQ: POAI) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for private and public entities. Ovarian cancer is difficult to treat and lethal, with survival rates much lower than other cancers that affect women. Recently, the battle against ovarian cancer has shifted strategy, and new optimism has come to the fore.

  • GlobeNewswire

    Predictive Oncology Reaches First Milestone in Building AI-driven Predictive Models of Ovarian Cancer

    Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announces that its Helomics subsidiary has begun to sequence tumor cases from its UPMC Magee collaboration (http://nnw.fm/4uKXL). Helomics’ partnership with the UPMC Magee Women’s Hospital focuses on analyzing the genomic and drug response profiles of women with ovarian cancer to build AI-driven predictive models’ terms of therapy response.

  • GlobeNewswire

    Predictive Oncology (NASDAQ: POAI) Featured in Broadcast on Big Data, AI’s Potential to Fight Cancer

    For some time, clinicians have been utilizing key genomic data to understand a patient’s individual tumor type in attempts to effectively prescribe therapies that will work. The precision-medicine space has a real unmet need, with a surging demand for a multi-omic approach rather than just genomics to better understand and treat the complexities of cancer.

  • GlobeNewswire

    Predictive Oncology (NASDAQ: POAI) Featured in NetworkNewsWire Publication Discussing Power of Data Plus AI in Precision Medicine

    NEW YORK, Oct. 30, 2019 (GLOBE NEWSWIRE) -- via NetworkWire — Predictive Oncology (NASDAQ: POAI) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for private and public entities. The field of precision medicine has latched upon what may well be the Holy Grail in the fight against cancer. When big data are utilized by teams of pathologists, data can be incredibly helpful, but when the right data are comprehensively analyzed by artificial intelligence (AI)-powered models, the data can be downright lifesaving.

  • GlobeNewswire

    Predictive Oncology: Helomics to present initial findings from its analysis of UK 100,000 Genomes Project data towards its goal of building AI-driven predictive models of ovarian cancer

    Predictive Oncology (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announces that Helomics CTO Dr. Mark Collins will speak during the scientific session of the conference, and will participate in an invite-only session on the expansion of the UK100K GP to 5 Million genomes.

  • GlobeNewswire

    Skyline Medical, a Division of Predictive Oncology Inc. (POAI), Sells 10 STREAMWAY® Systems to Prominent Teaching Hospital

    Skyline Medical, a subsidiary of POAI, continues to forge the standardization of waste fluid management with its sale of 10 systems in Rochester, NY. POAI continues to impress, innovate with disruptive technological advancements in the healthcare industry.

  • GlobeNewswire

    Predictive Oncology Inc. Announces Pricing of Public Offering of Up to $3,167,768.50 of Common Stock

    Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive” or “the Company”) today announced the pricing of its previously announced public offering of its common stock, with anticipated gross proceeds of up to $3,167,768.50, before deducting placement agent fees and expenses and offering expenses payable by the Company. The Company is offering 6,335,537 shares on a “best efforts” basis, at a price of $0.50 per share. The offering is expected to close on or about October 4, 2019, subject to customary closing conditions.

  • GlobeNewswire

    Predictive Oncology Inc. (POAI) Sells 10 STREAMWAY® Systems to Prominent Teaching Hospital

    Skyline Medical, a subsidiary of POAI, continues to forge the standardization of waste fluid management with its sale of 10 systems in Rochester, NY. POAI continues to impress, innovate with disruptive technological advancements in the healthcare industry.

  • GlobeNewswire

    Predictive Oncology Inc. Announces Proposed Public Offering of Common Stock

    Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive” or “the Company”) today announced a proposed public offering of its common stock. Dawson James Securities, Inc. and Paulson Investment Company, LLC are acting as exclusive placement agents for the offering. The offering of the securities will be made only by means of a prospectus supplement and accompanying prospectus.

  • GlobeNewswire

    Predictive Oncology Inc. Announces Repayment or Extension of Promissory Notes due September 28, 2019

    Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive” or “the Company”) today announced that its secured promissory notes that were due September 28, 2019 have been repaid or extended. On September 27, 2019, the Company repaid the remaining principal and interest balance of $478,590 on one of such notes. On the same date, the Company obtained a new investment of $700,000 from a private investor in exchange for a new 8% secured promissory note due on March 27, 2020 with an original principal amount of $847,500.

  • GlobeNewswire

    Coverage Initiated for Predictive Oncology via NetworkNewsWire

    NEW YORK, Sept. 19, 2019 -- via NetworkWire – Predictive Oncology (NASDAQ: POAI), an innovative company focused on the use of data and artificial intelligence (AI) to develop.

  • GlobeNewswire

    Predictive Oncology to Report Second Quarter 2019 Financial Results and Provide Company Update on Monday, August 19, 2019

    Predictive Oncology Inc., (NASDAQ: POAI) (“Predictive Oncology ” or “the Company”) an artificial intelligence (AI) and data-driven functional precision medicine company with the mission of improving the standard of care for cancer patients through innovative data-driven products and services, today announces it will report financial results for the quarter ended June 30, 2019 on Monday, August 19, 2019 after the market close. Management will host a conference call that same day at 5:30 p.m. Eastern Time, rather than 4:30pm, as previously announced, to review financial results, corporate highlights, and provide an update on developments. All callers should dial in approximately 10 minutes prior to the scheduled start time and ask to be joined into the Predictive Oncology call.

  • GlobeNewswire

    Predictive Oncology’s Skyline Medical Division Expands Its Asian Market Share with First-Ever Orders of STREAMWAY Systems in India

    Predictive Oncology, Inc. (Nasdaq: POAI) (“Predictive Oncology” or “the Company”), today announced its Skyline Medical division has received its first order from India for four machines to be sold to local hospitals. “The sale of these four STREAMWAY units in India marks our entry into that country, and is an exciting milestone in our continued market expansion,” commented Dr. Carl Schwartz, chief executive officer of Predictive Oncology. To be added to the Predictive Oncology database, please email Info@MoneyInfo-llc.com with your email address.

  • GlobeNewswire

    Predictive Oncology Subsidiary Helomics Collaborates with UPMC to Establish a Data and Artificial Intelligence-Driven Approach to Treating Ovarian Cancer

    Predictive Oncology (Nasdaq: POAI) subsidiary Helomics, an artificial intelligence (AI) and data-driven functional precision medicine company with the mission of improving the standard of care for cancer patients through innovative data-driven products and services, today announced a joint collaborative agreement with UPMC to study the use of artificial intelligence to improve clinical decision making for ovarian cancer patients. Helomics is a subsidiary of Predictive Oncology Inc., a company focused on applying artificial intelligence to personalized medicine and drug discovery.

  • GlobeNewswire

    Predictive Oncology Subsidiary, Helomics, Signs Collaborative Research Agreement with ChemImage to Expand Personalized Medicine to Prostate Cancer Prognosis and Treatment

    Predictive Oncology (Nasdaq: POAI) (“Predictive Oncology” or “the Company”), a company focused on applying artificial intelligence to personalized medicine and drug discovery, announced today it has signed a collaborative research agreement with Pittsburgh, Pa.-based molecular imaging company, ChemImage, to establish the feasibility of coupling genomics to Raman spectroscopy to better determine disease progression in prostate cancer. “Helomics’ ability to quickly generate data through our ‘multi-omic’ approach, coupled to our artificial intelligence (AI) technology, is a natural fit with companies like ChemImage, which is seeking a better understanding of disease progression through fusing together of ChemImage’s core Raman data with genomic data generated by Helomics,” commented Gerald Vardzel, president of Helomics.